A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis (ICONIC-PsA 2)

April 30, 2026 updated by: Janssen Research & Development, LLC

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

750

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Argentina
      • Buenos Aires, Argentina, B1643CRO
        • Recruiting
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Argentina, C1406AGA
        • Recruiting
        • ARCIS Salud SRL Aprillus asistencia e investigacion
      • Buenos Aires, Argentina, C1426
        • Recruiting
        • Hospital Militar Central Cir. My. Dr. Cosme Argerich
      • Ciudad de Buenos Aires, Argentina, C1431
        • Recruiting
        • Arsema
      • Ciudad de San Miguel de Tucuman, Argentina, T4000AXL
        • Recruiting
        • Centro Medico Privado de Reumatologia Tucuman
      • San Fernando, Argentina, B1646GHP
        • Recruiting
        • MR Medicina Reumatologica
  • Australia
      • Ipswich, Australia, 4305
        • Recruiting
        • Ipswich Hospital
      • Maroochydore, Australia, 4558
        • Recruiting
        • Rheumatology Research Unit
      • South Woodville, Australia, 5011
        • Recruiting
        • Queen Elizabeth Hospital
      • St Leonards, Australia, 2065
        • Recruiting
        • Royal North Shore Hospital
      • Tiwi, Australia, 0810
        • Recruiting
        • Royal Darwin Hospital
  • Brazil
      • Belo Horizonte, Brazil, 30130 100
        • Recruiting
        • Universidade Federal de Minas Gerais UFMG Faculdade de Medicina
      • Porto Alegre, Brazil, 90480 000
        • Recruiting
        • LMK Servicos Medicos S S
      • São José do Rio Preto, Brazil, 15090-000
        • Recruiting
        • Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base
      • São Paulo, Brazil, 01236030
        • Recruiting
        • BR TRIALS Ensaios Clinicos e Consultoria Ltda
      • São Paulo, Brazil, 04266 010
        • Recruiting
        • CEPIC Centro Paulista de Investigacao Clinica e Servicos Medicos
      • São Paulo, Brazil, 05403 900
        • Recruiting
        • Hospital das Clinicas da Faculdade de Medicina da USP
  • Bulgaria
      • Plovdiv, Bulgaria, 4001
        • Recruiting
        • UMHAT Kaspela
      • Plovdiv, Bulgaria, 4003
        • Recruiting
        • Multiprofile Hospital for Active Treatment Plovdiv
      • Sliven, Bulgaria, 8801
        • Recruiting
        • Diagnostic Consulting Center I Sliven
      • Sofia, Bulgaria, 1431
        • Recruiting
        • Diagnostic-Consultative Center (DCC) Aleksandrovska
      • Sofia, Bulgaria, 1750
        • Recruiting
        • ASIMP Rheumatology Centre St Irina EOOD
      • Sofia, Bulgaria, 1612
        • Recruiting
        • UMHAT St. Ivan Rilski
      • Sofia, Bulgaria, 1336
        • Recruiting
        • Multiprofile Hospital for Active Treatment - MHAT Lyulin EAD
      • Sofia, Bulgaria, 1407
        • Completed
        • MC Ekselsior
  • Canada
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1C 5B8
        • Recruiting
        • Eastern Regional Health Authority St Clares Mercy Hospital
    • Ontario
      • Orillia, Ontario, Canada, L3V 1T5
        • Recruiting
        • The Waterside Clinic
      • Toronto, Ontario, Canada, M5S 1B1
        • Recruiting
        • Womens College Hospital
      • Waterloo, Ontario, Canada, N2J 1C4
        • Completed
        • Alliance Clinical Trials
      • Windsor, Ontario, Canada, N8X 1T3
        • Recruiting
        • Dr Sabeen Anwar Medicine Professional Corporation
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
        • Recruiting
        • Hospital Maisonneuve-Rosemont
      • Trois-Rivières, Quebec, Canada, G9A 3X2
        • Recruiting
        • Centre de Recherche Musculo Squelettique
  • China
      • Beijing, China, 100191
        • Recruiting
        • Peking University Third Hospital
      • Beijing, China, 100730
        • Recruiting
        • Beijing Tong Ren Hospital Capital Medical University
      • Changchun, China, 130021
        • Recruiting
        • The First Bethune Hospital of Jilin University
      • Changsha, China, 410008
        • Recruiting
        • Xiangya Hospital Central South University
      • Chengdu, China, 610041
        • Recruiting
        • West China Hospital Sichuan University
      • Chengdu, China, 610072
        • Recruiting
        • Sichuan Provincial Peoples Hospital
      • Chongqing, China, 400016
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
      • Guangzhou, China, 510515
        • Active, not recruiting
        • Nanfang Hospital of Southern Medical Hospital
      • Guiyang, China, 550004
        • Recruiting
        • The Affiliated Hospital of Guizhou Medical University
      • Hangzhou, China, 310018
        • Recruiting
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Jiaxing, China, 314001
        • Recruiting
        • The First hospital of Jiaxing
      • Jinhua, China, 321013
        • Recruiting
        • Jinhua Municipal Central Hospital
      • Linyi, China, 276002
        • Recruiting
        • Linyi City People Hospital
      • Nanchang, China, 330008
        • Recruiting
        • The Second Affiliated Hospital of Nanchang University
      • Nantong, China, 226001
        • Recruiting
        • Affiliated Hospital of Nantong University
      • Pingxiang, China, 337055
        • Recruiting
        • Pingxiang People's Hospital
      • Shanghai, China, 200040
        • Recruiting
        • Huashan Hospital Fudan University
      • Shanghai, China, 200443
        • Recruiting
        • Shanghai Skin Disease Hospital
      • Shenzhen, China, 518020
        • Recruiting
        • Shenzhen People s Hospital
      • Suzhou, China, 215004
        • Recruiting
        • Second Affiliated Hospital of Soochow University
      • Taiyuan, China, 030032
        • Recruiting
        • Shanxi Bethune Hospital
      • Wenzhou, China, 325000
        • Recruiting
        • The First Affiliated Hospital of Wenzhou Medical University
      • Xi'an, China, 710006
        • Recruiting
        • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Czechia
      • Brno, Czechia, 63800
        • Recruiting
        • Revmatologie s r o
      • Brno, Czechia, 615 00
        • Recruiting
        • Revmacentrum MUDr Mostera s r o
      • Břeclav, Czechia, 690 02
        • Recruiting
        • RHEUMA s r o
      • Hlučín, Czechia, 748 01
        • Recruiting
        • L K N Arthrocentrum
      • Ostrava, Czechia, 70200
        • Recruiting
        • CCR Ostrava S R O
      • Ostrava, Czechia, 708 00
        • Recruiting
        • MUDr Rosypalova s r o
      • Prague, Czechia, 15000
        • Recruiting
        • FN Motol
      • Uherské Hradiště, Czechia, 68601
        • Recruiting
        • Medical Plus S R O
      • Zlín, Czechia, 76001
        • Recruiting
        • PV Medical S R O
  • Denmark
      • Aarhus N, Denmark, 8200
        • Recruiting
        • Aarhus University Hospital
      • Esbjerg, Denmark, 6700
        • Recruiting
        • Sydvestjysk Sygehus
      • Frederiksberg, Denmark, 2000
        • Recruiting
        • Frederiksberg Hospital
      • Herning, Denmark, 7400
        • Recruiting
        • Regionshospitalet Godstrup
      • Svendborg, Denmark, 5700
        • Recruiting
        • Svendborg Hospital Odense University Hospital
      • Vejle, Denmark, 7100
        • Recruiting
        • Vejle Sygehus
  • Germany
      • Berlin, Germany, 10117
        • Recruiting
        • Charite - Campus Mitte
      • Berlin, Germany, 10789
        • Recruiting
        • ISA - Interdisciplinary Study Association GmbH
      • Dresden, Germany, 01307
        • Recruiting
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Freiburg im Breisgau, Germany, 79106
        • Recruiting
        • Medizinische Fakultaet Der Albert Ludwigs Universitaet Freiburg
      • Hamburg, Germany, 20095
        • Recruiting
        • Hamburger Rheuma Forschungszentrum II
      • Herne, Germany, 44649
        • Recruiting
        • Rheumazentrum Ruhrgebiet
      • Langenau, Germany, 89129
        • Recruiting
        • Praxis Dr. med. Beate Schwarz - Germany
      • Ratingen, Germany, 40878
        • Completed
        • Rheumaforschung - Studienambulanz Dr. Wassenberg
      • Tübingen, Germany, 72076
        • Recruiting
        • Universitätsklinikum Tübingen
  • Hong Kong
      • Hong Kong, Hong Kong
        • Recruiting
        • Queen Mary Hospital
      • Hong Kong, Hong Kong, 000000
        • Recruiting
        • Prince of Wales Hospital
  • Hungary
      • Budapest, Hungary, 1152
        • Recruiting
        • Uno Medical Trials Ltd.
      • Budapest, Hungary, 1023
        • Recruiting
        • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
      • Budapest, Hungary, 1027
        • Recruiting
        • Revita Kft
      • Budapest, Hungary, 1134
        • Recruiting
        • Qualiclinic Kft
      • Debrecen, Hungary, 4032
        • Recruiting
        • Debreceni Egyetem Reumatologiai Klinika
      • Gyula, Hungary, 5700
        • Recruiting
        • Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
      • Kaposvár, Hungary, 7400
        • Completed
        • Obudai Egeszsegugyi Centrum Kft
      • Kecskemét, Hungary, 6000
        • Recruiting
        • Bacs Kiskun Varmegyei Oktatokorhaz
      • Szeged, Hungary, 6725
        • Recruiting
        • University of Szeged
      • Szolnok, Hungary, 5000
        • Recruiting
        • MAV Korhaz es Rendelointezet
      • Székesfehérvár, Hungary, 8000
        • Recruiting
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Veszprém, Hungary, 8200
        • Recruiting
        • Vital Medical Center Orvosi es Fogaszati Kozpont
  • India
      • Ahmedabad, India, 380060
        • Recruiting
        • Marengo CIMS Hospital
      • Bhubaneswar, India, 751005
        • Recruiting
        • Apollo Hospitals
      • Hubballi, India, 580021
        • Recruiting
        • Sushruta Multispeciality Hospital
      • Kolkata, India, 700054
        • Recruiting
        • Apollo Multispeciality Hospital Ltd
      • Mysuru, India, 570004
        • Recruiting
        • JSS Hospital
      • New Delhi, India, 110029
        • Recruiting
        • All India Institute of Medical Sciences
      • New Delhi, India, 1100776
        • Recruiting
        • Indraprastha Apollo Hospital
      • Noida, India, 201301
        • Recruiting
        • Fortis Hospital
      • Surat, India, 395002
        • Recruiting
        • SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre
  • Italy
      • Ancona, Italy, 60126
        • Recruiting
        • A.O. Universitaria Ospedali Riuniti di Ancona
      • Brescia, Italy, 25123
        • Recruiting
        • ASST Spedali Civili Brescia
      • Catania, Italy, 95124
        • Recruiting
        • Policlinico San Marco
      • Milan, Italy, 20132
        • Recruiting
        • Ospedale San Raffaele
      • Naples, Italy, 80138
        • Recruiting
        • Azienda Ospedaliero Universitaria Luigi Vanvitelli
      • Pavia, Italy, 27100
        • Recruiting
        • IRCCS Policlinico San Matteo
      • Roma, Italy, 00168
        • Recruiting
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Roma, Italy, 00133
        • Recruiting
        • Universita Degli Studi di Roma Tor Vergata
      • Rozzano, Italy, 20089
        • Recruiting
        • Istituto Clinico Humanitas
      • Siena, Italy, 53100
        • Recruiting
        • A O Universitaria Senese Ospedale Santa Maria alle Scotte
      • Udine, Italy, 33100
        • Recruiting
        • Ospedale S. Maria Della Misericordia
  • Japan
      • Chūōku, Japan, 104 8560
        • Recruiting
        • St. Luke's International Hospital
      • Hirakata, Japan, 573 1191
        • Recruiting
        • Kansai Medical University Hospital
      • Hyōgo, Japan, 6751392
        • Completed
        • Kita-harima Medical Center
      • Kitakyushu-shi, Japan, 807-8556
        • Recruiting
        • Hospital of the University of Occupational and Environmental Health
      • Nagoya, Japan, 467 8602
        • Recruiting
        • Nagoya City University Hospital
      • Osaka, Japan, 545 8586
        • Recruiting
        • Osaka Metropolitan University Hospital
      • Sanuki, Japan, 7692393
        • Recruiting
        • Sanuki Municipal Hospital
      • Sasebo, Japan, 857 1195
        • Recruiting
        • Sasebo Chuo Hospital
      • Sendai, Japan, 980 8574
        • Recruiting
        • Tohoku University Hospital
      • Shimotsuga Gun, Japan, 321 0293
        • Recruiting
        • Dokkyo Medical University Hospital
      • Tokyo, Japan, 181 8611
        • Recruiting
        • Kyorin University Hospital
      • Tsu, Japan, 514 8507
        • Recruiting
        • Mie University Hospital
      • Ōita, Japan, 870 0030
        • Recruiting
        • Maeshima Rheumatology Clinic
  • Malaysia
      • Alor Star, Malaysia, 05460
        • Recruiting
        • Hospital Sultanah Bahiyah
      • Batu Caves, Malaysia, 68100
        • Recruiting
        • Hospital Selayang
      • Ipoh, Malaysia, 30450
        • Recruiting
        • Hospital Raja Permaisuri Bainun
      • Johor Bahru, Malaysia, 81100
        • Recruiting
        • Hospital Sultan Ismail
      • Kuala Lumpur, Malaysia, 50586
        • Recruiting
        • Hospital Kuala Lumpur
      • Seremban, Malaysia, 70300
        • Recruiting
        • Hospital Tuanku Jaafar
  • Mexico
      • Culiacán, Mexico, 80000
        • Recruiting
        • Centro de Investigacion de Tratamientos Innovadores de Sinaloa
      • Guadalajara, Mexico, 44630
        • Recruiting
        • Grupo Clinico CATEI
      • Mexicali, Mexico, 45116
        • Recruiting
        • Centro Medico del Angel
      • Mexico City, Mexico, 03100
        • Recruiting
        • RM Pharma Specialists
      • Monterrey, Mexico, 64460
        • Recruiting
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • San Luis Potosí City, Mexico, 78213
        • Recruiting
        • Centro de Alta Especialidad en Reumatologia e Investigacion
  • Poland
      • Bialystok, Poland, 15-351
        • Recruiting
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Bialystok, Poland, 15-879
        • Recruiting
        • ClinicMed Daniluk Nowak Spolka Komandytowa
      • Bialystok, Poland, 15-375
        • Completed
        • Specderm Poznanska sp j
      • Bydgoszcz, Poland, 85-168
        • Recruiting
        • Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
      • Elblag, Poland, 82-300
        • Recruiting
        • Centrum Kliniczno Badawcze
      • Elblag, Poland, 82-300
        • Recruiting
        • Ambulatorium Sp. z o.o.
      • Gdynia, Poland, 81-338
        • Recruiting
        • Centrum Medyczne Pratia Gdynia
      • Krakow, Poland, 30-727
        • Recruiting
        • Pratia McM Krakow
      • Krakow, Poland, 30-002
        • Recruiting
        • Malopolskie Badania Kliniczne Sp z o o
      • Krakow, Poland, 30-002
        • Recruiting
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Krakow, Poland, 30-033
        • Recruiting
        • Centrum Medyczne All Med
      • Lodz, Poland, 90-265
        • Recruiting
        • Dermed Centrum Medyczne Sp z o o
      • Lublin, Poland, 20-607
        • Recruiting
        • Zespol Poradni Specjalistycznych Reumed Filia nr 1
      • Nadarzyn, Poland, 05-830
        • Recruiting
        • NZOZ Lecznica MAK MED S C
      • Torun, Poland, 87-100
        • Recruiting
        • MICS Centrum Medyczne Torun
      • Warsaw, Poland, 00-874
        • Recruiting
        • MICS Centrum Medyczne Warszawa
      • Warsaw, Poland, 02-665
        • Recruiting
        • Centrum Medyczne Reuma Park
      • Wroclaw, Poland, 52-416
        • Recruiting
        • Centrum Medyczne Oporow
      • Wroclaw, Poland, 51-503
        • Recruiting
        • DermMedica Sp z o o
  • Romania
      • Bucharest, Romania, 014142
        • Recruiting
        • S C Delta Health Care S R L
      • Craiova, Romania, 200400
        • Recruiting
        • Ecomed Research SRL
      • Iași, Romania, 700259
        • Recruiting
        • Centrul Medical Unirea
      • Râmnicu Vâlcea, Romania, 247065
        • Recruiting
        • Medaudio Optica S R L
  • Spain
      • A Coruña, Spain, 15006
        • Recruiting
        • Hosp Univ A Coruna
      • Córdoba, Spain, 14004
        • Recruiting
        • Hosp Reina Sofia
      • L'Hospitalet de Llobregat, Spain, 08907
        • Recruiting
        • Hosp. Univ. de Bellvitge
      • Madrid, Spain, 28031
        • Recruiting
        • Hosp. Univ. Infanta Leonor
      • Málaga, Spain, 29009
        • Recruiting
        • Hosp Regional Univ de Malaga
      • Santander, Spain, 39008
        • Recruiting
        • Hosp. Univ. Marques de Valdecilla
      • Santiago de Compostela, Spain, 15706
        • Recruiting
        • Hosp. Clinico Univ. de Santiago
      • Seville, Spain, 41013
        • Recruiting
        • Hosp. Virgen Del Rocio
      • Seville, Spain, 41009
        • Recruiting
        • Hosp. Virgen Macarena
      • Seville, Spain, 41010
        • Recruiting
        • Hosp. Infanta Luisa
  • Taiwan
      • Hsinchu, Taiwan, 300
        • Recruiting
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City, Taiwan, 83301
        • Recruiting
        • Kaohsiung Chang Gung Memorial Hospital
      • Tainan, Taiwan, 710
        • Recruiting
        • Chi Mei Medical Center
      • Taipei, Taiwan, 112
        • Recruiting
        • Taipei Veterans General Hospital
  • Thailand
      • Bangkok, Thailand, 10700
        • Recruiting
        • Siriraj Hospital
      • Bangkok, Thailand, 10400
        • Recruiting
        • Phramongkutklao Hospital
      • Bangkok, Thailand, 10400
        • Recruiting
        • Rajavithi Hospital
      • Changwat Sara Buri, Thailand, 18000
        • Recruiting
        • Saraburi Hospital
      • Songkhla, Thailand, 90110
        • Recruiting
        • Songklanagarind Hospital
  • United Kingdom
      • Barnet, United Kingdom, EN5 3DJ
        • Recruiting
        • Royal Free London NHS Foundation Trust
      • Basingstoke, United Kingdom, RG24 9NA
        • Recruiting
        • Basingstoke and North Hampshire Hospital
      • Christchurch, United Kingdom, BH23 2JX
        • Recruiting
        • University Hospitals Dorset NHS Foundation Trust
      • Edinburgh, United Kingdom, EH4 2XU
        • Recruiting
        • Western General Hospital
      • Glasgow, United Kingdom, G31 2ER
        • Recruiting
        • Glasgow Royal Infirmary
      • Hereford, United Kingdom, HR1 2ER
        • Recruiting
        • Hereford County Hospital
      • Larbert, United Kingdom, FK5 4WR
        • Recruiting
        • Forth Valley Royal Hospital
      • Staffordshire, United Kingdom, ST6 7AG
        • Recruiting
        • Haywood Hospital
      • Torquay, United Kingdom, TQ2 7AA
        • Recruiting
        • Torbay Hospital-Devon
      • Wolverhampton, United Kingdom, WV10 0QP
        • Recruiting
        • New Cross Hospital
      • Wrexham, United Kingdom, LL13 7TD
        • Recruiting
        • Betsi Cadwaladr University Health Board BCUHB
  • United States
    • Arizona
      • Glendale, Arizona, United States, 85306
        • Recruiting
        • AARA Clinical Research
      • Mesa, Arizona, United States, 85210
        • Recruiting
        • AARA Clinical Research 1
    • Arkansas
      • Jonesboro, Arkansas, United States, 72401
        • Recruiting
        • Arthritis and Rheumatism Associates ARA Jonesboro
    • Florida
      • Clearwater, Florida, United States, 33765
        • Recruiting
        • Clinical Research of West Florida
      • DeBary, Florida, United States, 32713
        • Recruiting
        • Omega Research Consultants
      • New Port Richey, Florida, United States, 34652
        • Recruiting
        • Suncoast Clinical Research
      • Plantation, Florida, United States, 33324
        • Recruiting
        • Integral Rheumatology And Immunology Specialists
      • Tampa, Florida, United States, 33606
        • Recruiting
        • Clinical Research of West Florida 1
    • Illinois
      • Skokie, Illinois, United States, 60076
        • Suspended
        • Clinic of Robert Hozman
    • Maryland
      • Hagerstown, Maryland, United States, 21740
        • Recruiting
        • Klein And Associates M D P A
    • Massachusetts
      • Brookline, Massachusetts, United States, 02446
        • Completed
        • DM Clinical Research 1
    • Minnesota
      • Eagan, Minnesota, United States, 55123
        • Recruiting
        • St Paul Rheumatology PA
    • New Mexico
      • Albuquerque, New Mexico, United States, 87102
        • Recruiting
        • Albuquerque Rehabilitation and Rheumatology
    • North Carolina
      • Charlotte, North Carolina, United States, 28204
        • Recruiting
        • Joint and Muscle Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73116
        • Recruiting
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635
        • Recruiting
        • Altoona Center for Clinical Research
    • Texas
      • Allen, Texas, United States, 75013
        • Recruiting
        • Arthritis and Rheumatology Research Institute
      • Dallas, Texas, United States, 75390
        • Recruiting
        • UT Southwestern
      • Harlingen, Texas, United States, 78550
        • Suspended
        • Naiara Alvarez MD Integrative Rheumatology of South TX
      • Irving, Texas, United States, 75039
        • Recruiting
        • AARA Clinical Research Lone Star Arthritis and Rheumatology
      • Tomball, Texas, United States, 77375
        • Recruiting
        • DM Clinical Research
      • Waco, Texas, United States, 76710
        • Recruiting
        • Velocity Clinical Research
    • Washington
      • Seattle, Washington, United States, 98104
        • Recruiting
        • Seattle Rheumatology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have active psoriatic arthritis (PsA) despite current or previous use of greater than or equal to (>=) 1 of the following: a. Non-biologic disease-modifying antirheumatic drug (DMARD) therapy; b. Apremilast therapy; c. Biologic-agent (limited to only 1)
  • Have a diagnosis of PsA for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) >= 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
  • Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Have active plaque psoriasis with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with psoriasis
  • A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion Criteria:

  • Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
  • Currently has a malignancy or has a history of malignancy within 5 years prior to screening
  • Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients
  • Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or Lyme disease
  • Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group I: Icotrokinra Dose 1
Participants will receive icotrokinra Dose 1. Participants who have not discontinued will be eligible to enter a long term extension (LTE) and will continue to receive icotrokinra Dose 1.
Drug: Icotrokinra
Icotrokinra will be administered.
Other Names:
  • JNJ-77242113
Experimental: Group II: Icotrokinra Dose 2
Participants will receive icotrokinra Dose 2. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 2.
Drug: Icotrokinra
Icotrokinra will be administered.
Other Names:
  • JNJ-77242113
Placebo Comparator: Group III: Placebo
Participants will receive placebo matched to icotrokinra and will cross over to receive icotrokinra Dose 1 or Dose 2 at Week 16. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 1 or Dose 2.
Drug: Placebo
Placebo will be administered.
Drug: Icotrokinra
Icotrokinra will be administered.
Other Names:
  • JNJ-77242113

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
Time Frame: Week 16
The ACR 20 responders are participants with an improvement of greater than or equal to (>=) 20 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale (VAS), patient's global assessment of disease activity [arthritis, VAS] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
Week 16

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants Who Achieved Psoriatic Area and Severity Index (PASI) 75 Response at Week 16 Among Participants with Baseline Body Surface Area (BSA) Greater Than Equal to (>=) 3 Percent (%) and With Baseline IGA Score of >=2
Time Frame: Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants who achieved at least a 75 percent improvement from baseline in the PASI score.
Week 16
Proportion of Participants Who Achieved PASI 90 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Time Frame: Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
Week 16
Proportion of Participants Who Achieved PASI 100 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Time Frame: Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants who achieved at least a 100 percent improvement from baseline in the PASI score.
Week 16
Proportion of Participants with an Investigator Global Assessment (IGA) Psoriasis Score of 0 or 1 And >=2 Grade Improvement From Baseline at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Time Frame: Week 16
Proportion of participants with an IGA psoriasis score of 0 or 1 And >=2 grade improvement from baseline at Week 16 among participants with >=3% BSA and an IGA Score of >=2 at Baseline will be reported. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling, each using a 5-point scale: using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema, and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Week 16
Proportion of Participants who Achieved an ACR 50 Response at Week 16
Time Frame: Week 16
The ACR 50 responders are participants with an improvement of >= 50% from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain VAS, patient's global assessment of disease activity (arthritis, VAS) scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
Week 16
Proportion of Participants who Achieved an ACR 70 Response at Week 16
Time Frame: Week 16
The ACR 70 responders are participants with an improvement of >= 70% from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain VAS, patient's global assessment of disease activity (arthritis, VAS) scale, Physician's global assessment of disease activity VAS scale, health assessment questionnaire and C-reactive protein).
Week 16
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score At Week 16
Time Frame: From baseline up to Week 16
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
From baseline up to Week 16
Changes From Baseline in 36 Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Time Frame: From baseline up to Week 16
SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a domain was an average of the individual question scores, which were scaled 0 to 100 (100=highest level of functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).
From baseline up to Week 16
Proportion of Participants With Resolution of Enthesitis at Week 16 Among Those With Enthesitis at Baseline
Time Frame: Week 16
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Week 16
Change From Baseline in Enthesitis Score at Week 16 in Participants With Enthesitis at Baseline
Time Frame: Baseline and Week 16
Enthesitis will be assessed using the LEI. The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Baseline and Week 16
Proportion of Participants With Resolution of Dactylitis at Week 16 Among Those With Dactylitis at Baseline
Time Frame: Week 16
Dactylitis is characterized by swelling of the entire finger or toe. Presence and severity of dactylitis will be assessed in both hand and feet using a scoring system from 0 to 3 (0: no dactylitis, 1: mild dactylitis, 2: moderate dactylitis, 3: severe dactylitis). The result for each digit are summed to produce a final dactylitis score with a range from 0 to 60. Higher score indicates greater severity.
Week 16
Change From Baseline in Dactylitis Score at Week 16 in Participants With Dactylitis at Baseline
Time Frame: From baseline up to Week 16
Dactylitis is characterized by swelling of the entire finger or toe. Presence and severity of dactylitis will be assessed in both hand and feet using a scoring system from 0 to 3 (0: no dactylitis, 1: mild dactylitis, 2: moderate dactylitis, 3: severe dactylitis). The result for each digit are summed to produce a final dactylitis score with a range from 0 to 60. Change from baseline in dactylitis score measure the change in dactylitis, where a negative change indicates an improvement and a positive change indicates a worsening.
From baseline up to Week 16
Proportion of Participants who Achieved Minimal Disease Activity (MDA) at Week 16
Time Frame: Week 16
MDA criteria are a composite of 7 outcome measures used in PsA. Participants are classified as achieving MDA if they fulfill at least 5 out of the 7 outcome measures: tender joint count less than or equal to (<=) 1; swollen joint count <= 1; psoriasis activity and severity index <= 1 or body surface area <= 3 percent (%); patient pain VAS score of <= 15; patient global disease activity VAS (arthritis and psoriasis) score of <= 20; health assessment questionnaire (HAQ) score <= 0.5; and tender entheseal points <= 1.
Week 16
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16
Time Frame: From baseline up to Week 16
The FACIT-fatigue is a self-administered, 13 item questionnaire measuring items on tiredness, weakness, and difficulty conducting usual activities due to fatigue. Responses to all items are rated on a 5-point Likert response scale ranging from 0 "not at all" to 4 "very much." The total score ranges from 0 to 52, with higher values indicating less fatigue.
From baseline up to Week 16

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Janssen Research & Development, LLC

Investigators

  • Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 9, 2025

Primary Completion (Estimated)

February 10, 2027

Study Completion (Estimated)

October 18, 2028

Study Registration Dates

First Submitted

January 29, 2025

First Submitted That Met QC Criteria

January 29, 2025

First Posted (Actual)

February 4, 2025

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 77242113PSA3002 (Janssen Research & Development, LLC)
  • 2024-517284-23-00 (Registry Identifier: EUCT number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthritis, Psoriatic

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe